While the panels recommendations arent binding, they are expected to help shape the FDAs final decision.
Medication regimen, given after L-NAME administration, included a total dose of 10 g/kg or 10 ng/kg of BPC 157 via retrobulbar application in each eye, 1 g/0.1 ml of saline/each eye or 1 ng/0.1 ml saline/each eye, or saline only via retrobulbar application in each eye (0.1 ml/each eye)
BPC-157 had been suggested to have healing effects on the gastrointestinal tract and various other organs and tissues [1, 2, 3, 4, 5, 6]
If a compound has a 4-hour half-life, its concentration will be halved every 4 hours
This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease and is not intended for ingestion by humans or animals.